A phase II trial of sunitinib in women with metastatic or recurrent endometrial carcinoma: a study of the Princess Margaret, Chicago and California Consortia (Q46078145)

From Wikidata

Jump to navigation Jump to search

scientific article published on 29 May 2014

Language	Label	Description	Also known as
English	A phase II trial of sunitinib in women with metastatic or recurrent endometrial carcinoma: a study of the Princess Margaret, Chicago and California Consortia	scientific article published on 29 May 2014

Statements

scholarly article

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/24882554

A phase II trial of sunitinib in women with metastatic or recurrent endometrial carcinoma: a study of the Princess Margaret, Chicago and California Consortia (English)

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/24882554

0 references

phase II clinical trial

0 references

endometrial carcinoma

1 reference

based on heuristic

inferred from title

author name string

Vincent Castonguay

1

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/24882554

Stephanie Lheureux

2

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/24882554

Stephen Welch

3

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/24882554

Helen J Mackay

4

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/24882554

Hal Hirte

5

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/24882554

Gini Fleming

6

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/24882554

R Morgan

7

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/24882554

Lisa Wang

8

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/24882554

Chantale Blattler

9

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/24882554

Percy S Ivy

10

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/24882554

Amit M Oza

11

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/24882554

language of work or name

0 references

publication date

29 May 2014

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/24882554

Gynecologic Oncology

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/24882554

134

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/24882554

2

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/24882554

274-280

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/24882554

Cancer statistics, 2013

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.05.016

7 January 2021

Treatment options for advanced endometrial carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.05.016

7 January 2021

Recent advances in systemic therapy for advanced endometrial cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.05.016

7 January 2021

Late-Breaking Abstract 1: Randomized phase III noninferiority trial of first line chemotherapy for metastatic or recurrent endometrial carcinoma: A Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.05.016

7 January 2021

Contemporary management of endometrial cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.05.016

7 January 2021

Phase II trial of ixabepilone as second-line treatment in advanced endometrial cancer: gynecologic oncology group trial 129-P.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.05.016

7 January 2021

Activity of paclitaxel as second-line chemotherapy in endometrial carcinoma: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.05.016

7 January 2021

A phase II trial of topotecan in patients with advanced, persistent, or recurrent endometrial carcinoma: a gynecologic oncology group study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.05.016

7 January 2021

Phase II trial of the pegylated liposomal doxorubicin in previously treated metastatic endometrial cancer: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.05.016

7 January 2021

What is the role of chemotherapy in endometrial cancer?

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.05.016

7 January 2021

A phase II trial of thalidomide in patients with refractory endometrial cancer and correlation with angiogenesis biomarkers: a Gynecologic Oncology Group study.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.05.016

7 January 2021

The angiogenic ?vascular endothelial growth factor/flk-1(KDR) receptor? pathway in patients with endometrial carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.05.016

7 January 2021

Vascular endothelial growth factor and platelet-derived endothelial cell growth factor expression are implicated in the angiogenesis of endometrial cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.05.016

7 January 2021

VEGF and its receptors (flt-1 and KDR/flk-1) as prognostic indicators in endometrial carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.05.016

7 January 2021

Prognostic significance of vascular endothelial growth factor and its receptors in endometrial carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.05.016

7 January 2021

Angiogenesis in endometrial carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.05.016

7 January 2021

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.05.016

7 January 2021

A phase 3 trial of bevacizumab in ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.05.016

7 January 2021

Incorporation of bevacizumab in the primary treatment of ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.05.016

7 January 2021

Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.05.016

7 January 2021

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.05.016

7 January 2021

Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.05.016

7 January 2021

Sunitinib: from rational design to clinical efficacy

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.05.016

7 January 2021

Sunitinib malate for the treatment of pancreatic neuroendocrine tumors

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.05.016

7 January 2021

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.05.016

7 January 2021

Phase II trial of continuous once-daily dosing of sunitinib as first-line treatment in patients with metastatic renal cell carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.05.016

7 January 2021

A phase II Gynecologic Oncology Group trial of ifosfamide and mesna in advanced or recurrent adenocarcinoma of the endometrium

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.05.016

7 January 2021

Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.05.016

7 January 2021

Ridaforolimus as a single agent in advanced endometrial cancer: results of a single-arm, phase 2 trial.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.05.016

7 January 2021

A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.05.016

7 January 2021

Everolimus as second- or third-line treatment of advanced endometrial cancer: ENDORAD, a phase II trial of GINECO.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.05.016

7 January 2021

A phase II study of sorafenib in advanced uterine carcinoma/carcinosarcoma: a trial of the Chicago, PMH, and California Phase II Consortia

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.05.016

7 January 2021

Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.05.016

7 January 2021

Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.05.016

7 January 2021

Safety and treatment patterns of angiogenesis inhibitors in patients with metastatic renal cell carcinoma: evidence from US community oncology clinics

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.05.016

7 January 2021

Body mass, diabetes and smoking, and endometrial cancer risk: a follow-up study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.05.016

7 January 2021

A phase II evaluation of aflibercept in the treatment of recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.05.016

7 January 2021

Targeting molecular pathways in endometrial cancer: a focus on the FGFR pathway

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.05.016

7 January 2021

Identifiers

10.1016/J.YGYNO.2014.05.016

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/24882554

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/24882554

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46078145&oldid=2091170412"